Back to Authors

Brewer, Jerry D.

Mayo Clinic

Mayo Clinic

Citations 66

Skin cancer surveillance and malignancies in patients with chronic lymphocytic leukemia (CLL).
Schwager, Susan M., Call, Timothy G. , Brewer, Jerry D., Mansfield, Aaron S. , Rabe, Kari G. , Shanafelt, Tait D.

Journal of Clinical Oncology | February 24, 2017 | Volume: 30 | Issue: 34_suppl | Pages: 184-184

10.1200/jco.2012.30.34_suppl.184 Get It

184 Background: Patients with CLL are at higher risk of developing melanoma and other skin malignancies. The survival of patients with melanoma is worse, stage for stage, in patients with CLL than patients without. It is thought that early diagnosis of skin cancer is critical to improving survival in CLL patients. To promote early diagnosis and education on skin cancer prevention, the Mayo Clinic CLL group has recommended that CLL patients be referred for full body skin evaluation within 6 months of diagnosis. We sought to determine adherence to these guidelines by our group and identify prevalence of skin malignancies within 6 months of diagnosis. Methods: We identified patients who lived within 30 miles of Mayo Clinic who were diagnosed with CLL between 01/01/2004 and 01/01/2012 using the Mayo Clinic CLL database. Charts were reviewed for skin examinations, referrals to dermatology/primary care within 6 months of diagnosis of CLL, and diagnosis of a skin malignancy. Results: There were 107 patients newly diagnosed with CLL included in this study. Of the 79 patients who received their primary care at Mayo Clinic, 40 (51%) had a documented whole body skin exam by either a dermatologist or primary care provider within six months of diagnosis. Nine of these 40 patients (23% of examined patients; 8% overall cohort) had a skin malignancy: 2 patients had basal cell carcinomas, 6 patients had squamous cell carcinomas, and 1 patient had malignant melanoma. Prophylactic skin care recommendations could be documented for only 28 (26%) of patients. Conclusions: At least 8% of patients in this locally dwelling cohort with newly diagnosed CLL had a skin malignancy identified within six months of diagnosis (number needed to screen for 1 skin cancer: 13). Of patients referred to dermatology 23% had a skin malignancy (number needed to screen: 4.3). Referrals for screening skin examinations at diagnosis in patients with CLL could have an immediate impact for this at-risk population.
Surgical Treatment and Outcomes of Patients With Extramammary Paget Disease: A Cohort Study
Kim, Sharon J. , Thompson, Agnieszka K., Zubair, Adeel , Otley, Clark C. , Arpey, Christopher J., Baum, Christian L. , Roenigk, Randall K., Lohse, Christine M. , Brewer, Jerry D.

Dermatologic Surgery | February 10, 2017 | Volume: 43 | Issue: 5 | Pages: 708-714

10.1097/dss.0000000000001051 Get It

BACKGROUND Extramammary Paget disease (EMPD) is a rare intraepithelial adenocarcinoma occurring mainly in the anogenital region. Traditional management with wide local excision has shown high recurrence rates, thus Mohs micrographic surgery (MMS) has emerged as a promising treatment option. OBJECTIVE To compare long-term outcomes after treatment with MMS or excision for primary EMPD. METHODS AND MATERIALS Retrospective cohort review was conducted for 207 patients with EMPD treated at Mayo Clinic in Rochester, MN, between 1961 and 2012. RESULTS Of the 25 patients treated with MMS, 19 primary tumors were included for outcome analysis, with an estimated 5-year recurrence-free survival rate of 91% (95% confidence interval [CI], 75–100) using Kaplan–Meier curve analysis. Of 158 patients treated with local excision, 124 were included for the analysis, with an estimated 5-year recurrence-free survival rate of 66% (95% CI, 56–78). The hazard ratio (HR) for association of treatment was 0.4 (95% CI, 0.10–1.65; p = .20). Estimated 5-year overall survival rates were 79% for MMS (95% CI, 61–100) and 68% for excision (95% CI, 59–78) (HR, 1.39 [95% CI, 0.69–2.82]; p = .36). CONCLUSION Although treatment of primary EMPD with MMS versus excision did not show statistical difference, MMS demonstrated favorable long-term outcomes and was associated with a higher recurrence-free survival rate.
A Comparison of Mohs Micrographic Surgery and Wide Local Excision for Treatment of Dermatofibrosarcoma Protuberans With Long-Term Follow-up: The Mayo Clinic Experience
Lowe, Garrett C., Onajin, Oluwakemi , Baum, Christian L. , Otley, Clark C. , Arpey, Christopher J., Roenigk, Randall K., Brewer, Jerry D.

Dermatologic Surgery | October 5, 2016 | Volume: 43 | Issue: 1 | Pages: 98-106

10.1097/dss.0000000000000910 Get It

BACKGROUND Dermatofibrosarcoma protuberans (DFSP) is a soft tissue tumor with slow infiltrative growth and local recurrence if inadequately excised. OBJECTIVE To compare long-term outcomes after Mohs micrographic surgery (MMS) and wide local excision (WLE). MATERIALS AND METHODS Records of patients with DFSP surgically treated with WLE or MMS from January 1955 through March 2012 were retrospectively reviewed. RESULTS Mean follow-up for patients treated with MMS (n = 67) and WLE (n = 91) was 4.8 and 5.7 years, respectively. Twenty-eight patients (30.8%) with WLE had recurrence (mean, 4.4 years), whereas only 2 (3.0%) with MMS had recurrence (1.0 and 2.6 years). Recurrence-free survival rates at 1, 5, 10, and 15 years were significantly higher with MMS (p < .001). Mean preoperative lesion sizes were similar (5–6 cm) between the 2 groups, whereas mean (standard deviation) postoperative defect sizes were 10.7 (4.3) cm and 8.8 (5.5) cm for WLE and MMS, respectively (p = .004). Primary closure was used for 73% of MMS cases, whereas WLE more commonly used flaps, grafts, or other closures (52%). Two Mohs layers typically were required for margin control. CONCLUSION Surgical excision with meticulous histologic evaluation of all surgical margins is needed for DFSP treatment to achieve long-term high cure rates and low morbidity.
Clinically atypical nevi following diode laser therapy
Ashack, Kurt , Brewer, Jerry D.

International Journal of Dermatology | August 6, 2016 | Volume: 56 | Issue: 5 | Pages: 579-580

10.1111/ijd.13376 Get It

Comparison of Sterile vs Nonsterile Gloves in Cutaneous Surgery and Common Outpatient Dental Procedures
Brewer, Jerry D., Gonzalez, Alexandra B., Baum, Christian L. , Arpey, Christopher J., Roenigk, Randall K., Otley, Clark C. , Erwin, Patricia J.

JAMA Dermatology | August 3, 2016 | Volume: 152 | Issue: 9 | Pages: 1008

10.1001/jamadermatol.2016.1965 Get It

A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy
Kottschade, Lisa A. , Brys, Adam K. , Peikert, Tobias, Ryder, Mabel , Raffals, Laura E., Brewer, Jerry D., Markovic, Svetomir, Kottschade, Lisa, Raffals, Laura E. , Mosca, Paul J. , Markovic, Svetomir N. , Ryder, Mabel

Melanoma Research | June 16, 2016 | Volume: 26 | Issue: 5 | Pages: 469-480

10.1097/cmr.0000000000000273 Get It

Immune-related Adverse Events (irAEs) are the most significant toxicities associated with the use of checkpoint inhibitors, and result from disinhibition of the host’s immune homeostasis. The adverse effects experienced from immunotherapy are significantly different from those of chemotherapy and, to a lesser extent, targeted therapy. Early recognition and diagnosis of these toxicities is often challenging, but is critically important because of the potentially life-threatening nature and associated morbidity. Gastrointestinal, dermatologic, endocrine, and liver toxicities are the most commonly observed. Less commonly, the eyes, pancreas, kidneys, lungs, bone marrow, or nervous system may be affected. Although most irAEs may resolve with supportive care or discontinuation of drug, in severe cases, they may require hospitalization and immune suppressants, such as steroids, and/or may even cause death. The management of immune-related side effects requires a multidisciplinary approach.
Incidence of atypical nevi in Olmsted County: an epidemiological study
Adaji, Afolake, Gaba, Prakriti , Lohse, Christine M. , Brewer, Jerry D.

Journal of Cutaneous Pathology | March 12, 2016 | Volume: 43 | Issue: 7 | Pages: 557-563

10.1111/cup.12709 Get It

BackgroundThe association of atypical nevi with melanoma and other forms of skin cancer has not been clearly defined.MethodsWe studied 631 patients with first lifetime diagnosis of mild, moderate or severely atypical nevus from 2000 through 2005, identified through a population‐based approach.ResultsAge at first diagnosis differed significantly between men and women (p<.001). Incidence rates peaked in the second through fourth decades in women and in the third, sixth and seventh decades in men. From 2000 through 2005, the overall age‐ and sex‐adjusted incidence rate of all degrees of atypical nevi was 76.0 per 100,000 person‐years. There were no statistically significant associations identified between the degree of atypia and the future development of basal cell carcinoma, squamous cell carcinoma or MM (p = 0.51, p = 0.28 and p = 0.19, respectively).ConclusionThere is no association between atypical nevi and the subsequent development of non‐melanoma skin cancer and MM. Incidence rates of atypical nevi are higher among younger women and older men. The association between degree of atypia and malignant melanoma warrants further study.
Carbon dioxide laser treatment for Hailey–Hailey disease: a retrospective chart review with patient‐reported outcomes
Hochwalt, Phillip C., Christensen, Kevin, Cantwell, Sean , Hocker, Thomas L., Otley, Clark C. , Brewer, Jerry D., Arpey, Christopher J., Roenigk, Randall K., Baum, Christian L. , Christensen, Kevin N, Cantwell, Sean R.

International Journal of Dermatology | October 13, 2015 | Volume: 54 | Issue: 11 | Pages: 1309-1314

10.1111/ijd.12991 Get It

AbstractBackgroundHailey–Hailey disease (HHD) is an autosomal dominant genodermatosis that leads to skin breakdown and blister formation, usually in intertriginous areas. Laser ablation is a known surgical treatment for HHD.ObjectivesWe report outcomes in a series of patients with HHD treated with carbon dioxide (CO2) laser ablation.MethodsA retrospective chart review of data for 13 patients who underwent CO2 laser ablation for HHD was conducted. Questionnaires assessing effectiveness, pain, healing time, recurrence, new disease, complications, additional ablation, improvement in quality of life (QoL), and overall satisfaction were completed by all patients.ResultsAll patients had been recalcitrant to previous treatments prior to CO2 laser ablation. Anatomic sites treated and anesthesia techniques for the procedure varied. The mean ± standard deviation (SD) score for the effectiveness of CO2 laser ablation for HHD was 9.3 ± 0.9 (maximum: 10). All patients reported improved QoL. No patient had recurring disease within the treatment field. Five patients underwent additional CO2 laser treatments at new sites. One patient reported postoperative infection. No other complications were identified. The mean ± SD score for overall satisfaction with CO2 laser ablation was 8.9 ± 1.1.ConclusionsTreatment with CO2 laser ablation is very effective and can lead to prolonged or permanent remission in most HHD patients. Patients are highly satisfied with the results and report a substantial improvement in QoL.
Incidence of Merkel cell carcinoma in Olmsted County, Minnesota: a population‐based study
Chang, Michael B., Weaver, Amy L. , Brewer, Jerry D.

International Journal of Dermatology | August 1, 2015 | Volume: 55 | Issue: 1 | Pages: No page available

10.1111/ijd.12812 Get It

AbstractBackgroundMerkel cell carcinoma (MCC) is a rare, aggressive, often cutaneous malignancy. The incidence has been estimated from national registries in the USA and elsewhere, and data indicate variations depending on the region studied. The objective of this study was to determine the incidence of MCC in Olmsted County (MN, USA).MethodsUsing the Rochester Epidemiology Project, which contains health records for all the residents of Olmsted County, we retrospectively reviewed the records for all cases of MCC from 1976 to 2011.ResultsThe overall annual age‐ and sex‐adjusted incidence of MCC in Olmsted County during 1976–2011 was 0.35 per 100,000 person‐years (95% CI, 0.14–0.57). The incidence tended to be higher among men than women with 0.69 per 100,000 (95% CI, 0.24–1.14) and 0.10 per 100,000 (95% CI, 0–0.24), respectively.ConclusionsThese data are within the range of previous MCC incidence reports, and the incidence of MCC in Olmsted County is consistent with rates reported in the remainder of the USA.
Incidence of Melanoma in Children: A Population‐Based Study in Olmsted County, Minnesota
Lowe, Garrett C., Brewer, Jerry D., Peters, Margot S. , Davis, Dawn M. R., Davis, Dawn Marie R.

Pediatric Dermatology | June 10, 2015 | Volume: 32 | Issue: 5 | Pages: 618-620

10.1111/pde.12621 Get It

AbstractBackgroundThe incidence of melanoma has been rising in the United States, with conflicting evidence regarding trends in children.MethodsWe identified patients 0 to 17 years old with a diagnosis of melanoma from January 1, 1970, through December 31, 2010, in Olmsted County, Minnesota. Information on survival and demographic characteristics was abstracted, and estimates of true incidence were calculated.ResultsThe estimated true incidence of melanoma in children from 1970 to 2010 was found to be 0.62 per 100,000 girls and 0.45 per 100,000 boys. The incidence of melanoma in this population did not increase with time after adjusting for age and sex. Only one case of metastatic disease (lymph node) was identified. Girls were more commonly affected and the mean age of disease onset was 14 years. Five of the seven melanomas in this population arose in association with a nevus, and none involved the trunk. Overall and disease‐specific survival rates were not calculated because all patients studied were alive at the last follow‐up.ConclusionThe estimated true incidence rates of pediatric melanoma from our population‐based study in Olmsted County, Minnesota, appear stable. This finding is in contrast to our prior research showing rapidly increasing incidence rates of melanoma in young and middle‐aged adults from the same population.